Astria Therapeutics Inc
NASDAQ:ATXS 4:00:00 PM EDT
| Market Cap (Intraday) | 422.14M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $7.34 |
| 50-Day MA | $6.77 |
| 200-Day MA | $6.55 |
Astria Therapeutics Inc Stock, NASDAQ:ATXS
22 Boston Wharf Road, 10th floor, Boston, Massachusetts 02210
United States of America
Phone: +1.617.349.1971
Number of Employees: 59
Description
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.